Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

11.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.8K
The Ras Gene02:38

The Ras Gene

5.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.6K
2.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.7K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic epidemiology, evolution, and transmission dynamics of porcine sapelovirus associated with diarrheic piglets.

Virulence·2026
Same author

Preoperative Prediction of High Mitotic Count in Gastrointestinal Stromal Tumors Using CT Features and Serologic Indicators: An Interpretable Model with Multicenter External Validation.

Journal of inflammation research·2026
Same author

Associations of trimethylamine N-oxide and its precursors with hypertensive disorders of pregnancy, its subtypes and blood pressure in the offspring: findings from the Shanghai Birth Cohort.

BMC pregnancy and childbirth·2026
Same author

Dictamnus dasycarpus Turcz. alleviates cholestatic liver injury: orchestrating tissue-divergent extracellular matrix remodeling across the gut-liver axis.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Invasive pericardial and pulmonary aspergillosis by uncommon <i>Aspergillus</i> species in anti-interferon-γ autoantibody-associated immunodeficiency: a case report.

Frontiers in medicine·2026
Same author

Exploration of anti-oomycete components from wild plants against <i>Phytophthora infestans</i>.

Frontiers in plant science·2026

Related Experiment Video

Updated: Apr 23, 2026

Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
08:36

Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues

Published on: May 26, 2018

14.7K

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications.

Yuhan Fang1,2,3, Xiaoqing Wang1,2,3, Kai Luo1,2,3

  • 1Department of General Surgery The Second Hospital of Dalian Medical University Dalian China.

Medcomm
|April 22, 2026
PubMed
Summary

Isocitrate dehydrogenase (IDH) mutations drive cancer by producing d-2-hydroxyglutarate (D-2HG), which harms the immune system. IDH inhibitors are effective treatments, but resistance necessitates combination strategies for better outcomes.

Keywords:
2‐hydroxyglutarateisocitrate dehydrogenase mutationtargeted inhibitorstherapeutic resistancetumor immune microenvironment

More Related Videos

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

7.3K

Related Experiment Videos

Last Updated: Apr 23, 2026

Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
08:36

Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues

Published on: May 26, 2018

14.7K
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.0K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

7.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Isocitrate dehydrogenase (IDH) mutations are key drivers in many cancers.
  • Mutant IDH produces d-2-hydroxyglutarate (D-2HG), impacting epigenetics and immune cells.
  • D-2HG suppresses T-cells, NK cells, and dendritic cells, altering the tumor microenvironment.

Purpose of the Study:

  • To review the mechanisms of mutant IDH in oncogenesis.
  • To evaluate the development and clinical translation of IDH inhibitors.
  • To discuss strategies for overcoming therapeutic resistance.

Main Methods:

  • Review of preclinical models and clinical trial data for IDH inhibitors.
  • Analysis of D-2HG's effects on tumor immunity.
  • Exploration of resistance mechanisms and combination therapies.

Main Results:

  • Selective allosteric IDH inhibitors show potent D-2HG suppression.
  • FDA-approved IDH inhibitors demonstrate efficacy in gliomas and acute myeloid leukemia.
  • Resistance mechanisms include mutations and metabolic reprogramming.

Conclusions:

  • IDH inhibitors represent a significant advancement in precision oncology.
  • Combination strategies with HMAs, targeted therapies, and immunomodulation are promising.
  • Emerging technologies like single-cell profiling will refine patient stratification and treatment efficacy.